Medline Inc. - Class A common stock (MDLN)

Is something seriously wrong with the automation expert, or is this a market overreaction and an opportunity to buy?

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Symbotic's big growth moves of 2025 should propel the company to new highs.

Medline is an appealing investment candidate – it has solid growth, operates in a steady industry, and a storied history.

Do you remember all of the surprises investors got in 2025? We had tariffs, AI upheaval, and even gold having a great year.

As the final bell rings on 2025, the U.S. initial public offering (IPO) market has emerged from its multi-year hibernation, not with a frantic sprint, but with a calculated and selective stride. After the stagnation of 2023 and the tentative recovery of 2024, the past twelve months have seen

The global healthcare landscape shifted decisively on December 16, 2025, with the public market return of Medline Industries (Nasdaq: MDLN). After four years under the stewardship of a private equity consortium—and decades of private family ownership before that—the medical supply titan has reclaimed its status as a public entity in the largest U.S. initial public [...]

In a stunning return to the public stage, Medline Industries (Nasdaq: MDLN) successfully executed the largest initial public offering (IPO) in the United States since 2021, pricing its shares at the top of its range and witnessing a massive first-day "pop" that has sent ripples through the financial world. The

The company's first day on the market underscored strong investor demand for scaled, profitable issuers as the U.S. IPO pipeline shows strength.